Reproducibility, Performance, and Clinical Utility of a Genetic Risk Prediction Model for Prostate Cancer in Japanese

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Akamatsu, Shusuke ^a,b   Takahashi, Atsushi ^a   Takata, Ryo ^a,c   Kubo, Michiaki ^a   Inoue, Takahiro ^b   Morizono, Takashi ^a   Tsunoda, Tatsuhiko ^a   Kamatani, Naoyuki ^a   Haiman, Christopher A ^d   Wan, Peggy ^d   Chen, Gary K ^d   Le Marchand, Loic ^e   Kolonel, Laurence N ^e   Henderson, Brian E ^d   Fujioka, Tomoaki ^a   Habuchi, Tomonori ^f   Nakamura, Yusuke ^g   Ogawa, Osamu ^b   Nakagawa, Hidewaki ^a  

^a RIKEN   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF HAWAII   (United States)

^f AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; AREA UNDER THE CURVE; ARTICLE; CARCINOGENESIS; CASE CONTROL STUDY; CLINICAL DECISION MAKING; CONTROLLED STUDY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC RISK PREDICTION MODEL; HUMAN; JAPANESE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PROSTATE CANCER; REPRODUCIBILITY; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; VALIDATION PROCESS;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; JAPAN; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; ROC CURVE;

EID: 84867389238     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046454     Document Type: Article

References (45)

1. Grönberg H, (2003) Prostate cancer epidemiology. Lancet 361: 859-864.
2. Matsuda T, Saika K, (2009) Comparison of time trends in prostate cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, Vols IV-IX. Jpn J Clin Oncol 39: 468-469.
3. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, et al. (2004) Human prostate cancer risk factors. Cancer 101: 2371-2490.
4. Pienta KJ, Esper PS, (1993) Risk factors for prostate cancer. Ann Intern Med 118: 793-803.
5. Loeb S, Catalona WJ, (2007) Prostate-specific antigen in clinical practice. Cancer Lett 249: 30-39.
6. Ito K, Ichinose Y, Kubota Y, Imai K, Yamanaka H, (1997) Clinicopathological features of prostate cancer detected by transrectal ultrasonography-guided systematic six-sextant biopsy. Int J Urol 4: 474-479.
7. Ito K, Ohi M, Yamamoto T, Miyamoto S, Kurokawa K, et al. (2002) The diagnostic accuracy of the age-adjusted and prostate volume-adjusted biopsy method in males with prostate specific antigen levels of 4.1-10.0 ng/mL. Cancer 95: 2112-2119.
8. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, et al. (2010) American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 60: 70-98.
9. Vickers AJ, Savage C, O'Brien MF, Lilja H, (2009) Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 27: 398-403.
10. Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, et al. (2011) A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. BJU Int 109: 1627-1635.
11. Amundadottir L, Sulem P, Gudmundsson J, Helgason A, Baker A, et al. (2006) A common variant associated with prostate cancer in European and African populations. Nat Genet 38: 652-658.
12. Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, et al. (2011) Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet 43: 570-573.
13. Yeager M, Chatterjee N, Ciampa J, Jacobs KB, Gonzalez-Bosquet J, et al. (2009) Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet 41: 1055-1057.
14. Gudmundsson J, Sulem P, Gudbjartsson D, Blondal T, Gylfason A, et al. (2009) Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet 41: 1122-1126.
15. Thomas G, Jacobs K, Yeager M, Kraft P, Wacholder S, et al. (2008) Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 40: 310-315.
16. Eeles R, Kote-Jarai Z, Al Olama A, Giles G, Guy M, et al. (2009) Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 41: 1116-1121.
17. Eeles R, Kote-Jarai Z, Giles G, Olama A, Guy M, et al. (2008) Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40: 316-321.
18. Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, et al. (2011) Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 43: 785-791.
19. Gudmundsson J, Sulem P, Rafnar T, Bergthorsson J, Manolescu A, et al. (2008) Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 40: 281-283.
20. Takata R, Akamatsu S, Kubo M, Takahashi A, Hosono N, et al. (2010) Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet 42: 751-754.
21. Nakagawa H, Akamatsu S, Takata R, Takahashi A, Kubo M, et al. (2012) Prostate cancer genomics, biology, and risk assessment through genome-wide association studies. Cancer Sci 103: 607-613.
22. Janssens AC, van Duijn CM, (2008) Genome-based prediction of common diseases: advances and prospects. Hum Mol Genet 17: R166-173.
23. Batra J, Lose F, Chambers S, Gardiner RA, Aitken J, et al. (2011) A replication study examining novel common single nucleotide polymorphisms identified through a prostate cancer genome-wide association study in a Japanese population. Am J Epidemiol 174: 1391-1395.
24. Lindström S, Schumacher FR, Campa D, Albanes D, Andriole G, et al. (2012) Replication of Five Prostate Cancer Loci Identified in an Asian Population-Results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev 21: 212-216.
25. Ghoussaini M, Song H, Koessler T, Al Olama AA, Kote-Jarai Z, et al. (2008) Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst 100: 962-966.
26. Chung S, Nakagawa H, Uemura M, Piao L, Ashikawa K, et al. (2011) Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci 102: 245-252.
27. Akamatsu S, Takata R, Haiman CA, Takahashi A, Inoue T, et al. (2012) Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nat Genet 44: 426-429.
28. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, et al. (2001) A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 46: 471-477.
29. Nakamura Y, (2007) The BioBank Japan Project. Clin Adv Hematol Oncol 5: 696-697.
30. Strope SA, Andriole GL, (2010) Prostate cancer screening: current status and future perspectives. Nat Rev Urol 7: 487-493.
31. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al. (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360: 1320-1328.
32. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, et al. (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360: 1310-1319.
33. Littrup PJ, Goodman AC, Mettlin CJ, Murphy GP, (1994) Cost analyses of prostate cancer screening: frameworks for discussion. Investigators of the American Cancer Society-National Prostate Cancer Detection Project. J Urol 152: 1873-1877.
34. Ekwueme DU, Stroud LA, Chen Y, (2007) Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies. Prev Chronic Dis 4: A100.
35. Schaid DJ, (2004) The complex genetic epidemiology of prostate cancer. Hum Mol Genet 13 Spec No 1: R103-121.
36. Kawakami S, Koga F, Fujii Y, Saito K, Yamamoto S, et al. (2008) History of malignancy is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram. Int J Urol 15: 1055-1060.
37. Zheng J, Liu F, Lin X, Wang X, Ding Q, et al. (2012) Predictive performance of prostate cancer risk in Chinese men using 33 reported prostate cancer risk-associated SNPs. Prostate 72: 577-583.
38. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, et al. (2008) Cumulative association of five genetic variants with prostate cancer. N Engl J Med 358: 910-919.
39. Zheng SL, Sun J, Wiklund F, Gao Z, Stattin P, et al. (2009) Genetic variants and family history predict prostate cancer similar to prostate-specific antigen. Clin Cancer Res 15: 1105-1111.
40. Aly M, Wiklund F, Xu J, Isaacs WB, Eklund M, et al. (2011) Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. Eur Urol 60: 21-28.
41. Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, et al. (2011) Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 43: 785-791.
42. Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, et al. (2010) Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res 70: 9742-9754.
43. Catalona WJ, Bailey-Wilson JE, Camp NJ, Chanock SJ, Cooney KA, et al. (2011) National Cancer Institute Prostate Cancer Genetics Workshop. Cancer Res 71: 3442-3446.
44. Gudmundsson J, Besenbacher S, Sulem P, Gudbjartsson DF, Olafsson I, et al. (2010) Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med 2: 62ra92.
45. Klein RJ, Hallden C, Gupta A, Savage CJ, Dahlin A, et al. (2011) Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. Eur Urol 61: 471-477.